$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2023 Q3 Form 10-Q Financial Statement

#000143774923023686 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.992M $3.079M
YoY Change 58.46% 206.37%
% of Gross Profit
Research & Development $8.717M $8.991M
YoY Change 278.03% 99.17%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.71M $12.07M
YoY Change 200.57% 118.69%
Operating Profit -$10.71M -$12.07M
YoY Change 200.57% 118.69%
Interest Expense $5.901K $12.76K
YoY Change -88.08% 66.13%
% of Operating Profit
Other Income/Expense, Net $230.1K -$365.9K
YoY Change 364.83% -297.02%
Pretax Income -$10.48M -$12.44M
YoY Change 198.25% 133.16%
Income Tax $12.12K $6.436K
% Of Pretax Income
Net Earnings -$10.50M -$12.40M
YoY Change 200.0% 133.96%
Net Earnings / Revenue
Basic Earnings Per Share -$0.44 -$0.55
Diluted Earnings Per Share -$0.44 -$0.55
COMMON SHARES
Basic Shares Outstanding 22.65M 20.63M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.972M $11.15M
YoY Change -78.56% -42.58%
Cash & Equivalents $4.972M $11.15M
Short-Term Investments
Other Short-Term Assets $414.7K $690.4K
YoY Change -51.15% -43.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.387M $11.84M
YoY Change -77.59% -42.64%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.00 $2.00
YoY Change 100.0%
TOTAL ASSETS
Total Short-Term Assets $5.387M $11.84M
Total Long-Term Assets $1.00 $2.00
Total Assets $5.387M $11.84M
YoY Change -77.59% -42.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.278M $2.648M
YoY Change 124.82% 3.72%
Accrued Expenses $7.532M $6.338M
YoY Change 513.41% 229.37%
Deferred Revenue
YoY Change
Short-Term Debt $222.5K $222.5K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.03M $9.208M
YoY Change 264.49% 105.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $873.4K $1.012M
YoY Change 726.31% 857.89%
Total Long-Term Liabilities $873.4K $1.012M
YoY Change 726.31% 857.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.03M $9.208M
Total Long-Term Liabilities $873.4K $1.012M
Total Liabilities $13.91M $10.22M
YoY Change 277.75% 123.01%
SHAREHOLDERS EQUITY
Retained Earnings -$120.7M -$110.2M
YoY Change 45.25% 38.62%
Common Stock $2.265K $2.265K
YoY Change 10.81% 49.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$8.519M $1.621M
YoY Change
Total Liabilities & Shareholders Equity $5.387M $11.84M
YoY Change -77.59% -42.64%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$10.50M -$12.40M
YoY Change 200.0% 133.96%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.178M -$5.317M
YoY Change 54.37% 32.89%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 350.0 5.213M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -6.178M -5.317M
Cash From Investing Activities
Cash From Financing Activities 350.0 5.213M
Net Change In Cash -6.178M -104.0K
YoY Change -263.78% -97.4%
FREE CASH FLOW
Cash From Operating Activities -$6.178M -$5.317M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
-456177 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
21361208 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39876 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28686460 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19420062 usd
CY2022Q2 rvph Prepaid Expenses Included In Accounts Payable
PrepaidExpensesIncludedInAccountsPayable
169314 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18519856 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
690440 usd
CY2023Q2 us-gaap Assets
Assets
11842022 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5784973 usd
CY2023Q2 rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5658257 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2620819 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001742927
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-365875 usd
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3520271 usd
CY2022Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
2519569 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6039840 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
567439 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6607279 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
12759 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
103080 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6436 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12442862 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12442862 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12316396 usd
rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
5677850 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5340704 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16060380 usd
rvph Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
70 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
79562 usd
us-gaap Net Income Loss
NetIncomeLoss
-12705712 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16060380 usd
us-gaap Net Income Loss
NetIncomeLoss
-19045405 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
445051 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-267031 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2672346 usd
us-gaap Share Based Compensation
ShareBasedCompensation
79562 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
286621 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-661972 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-871984 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1874328 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
3817989 usd
rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
88929 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13268624 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10267952 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
667500 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
445000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
-0 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5677850 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
70 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5900350 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
70 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7368274 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-10267882 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18519856 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29687944 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11151582 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3941 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
3981 usd
us-gaap Interest Paid Net
InterestPaidNet
20414 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q2 rvph Prepaid Expenses Included In Accounts Payable
PrepaidExpensesIncludedInAccountsPayable
0 usd
CY2023Q2 rvph Working Capital
WorkingCapital
2600000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110200000 usd
CY2023Q2 us-gaap Cash
Cash
11200000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-12400000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5300000 usd
us-gaap Net Income Loss
NetIncomeLoss
-19000000.0 usd
us-gaap Net Income Loss
NetIncomeLoss
-12700000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Use of estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not limited to, depreciative and amortization useful lives, assumptions used to calculate the fair value of stock-based compensation, warrant values, deferred taxes, and related valuation allowances. Actual results could differ materially from such estimates under different assumptions or circumstances.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Concentration of credit risk and other risks and uncertainties</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Currently, substantially all the Company’s cash and cash equivalents are held in demand deposit form at two financial institutions. Deposits in financial institutions may, from time to time, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not limited to, limited management resources, dependence upon medical acceptance of products in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company’s operating results may be materially affected by the foregoing factors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17577983
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15076630
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17577983
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15076630
CY2022Q3 us-gaap Share Price
SharePrice
2.20
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1303000
CY2023Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.74
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2620819 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39876 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2672346 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
79562 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4188195 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0343 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.90

Files In Submission

Name View Source Status
rvph-20230630_lab.xml Edgar Link unprocessable
rvph-20230630_cal.xml Edgar Link unprocessable
0001437749-23-023686-index-headers.html Edgar Link pending
0001437749-23-023686-index.html Edgar Link pending
0001437749-23-023686.txt Edgar Link pending
0001437749-23-023686-xbrl.zip Edgar Link pending
ex_557373.htm Edgar Link pending
ex_557374.htm Edgar Link pending
ex_557375.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20230630.xsd Edgar Link pending
rvph20230630_10q.htm Edgar Link pending
Show.js Edgar Link pending
rvph-20230630_def.xml Edgar Link unprocessable
rvph-20230630_pre.xml Edgar Link unprocessable
rvph20230630_10q_htm.xml Edgar Link completed